DELRAY BEACH, Fla. - November 6, 2012 (Investorideas.com Newswire,
www.biodefensestocks.com) PositiveID Corporation (
OTCBB: PSID)
("PositiveID" or "Company"), an emerging growth company and developer
of airborne bio-threat detection systems for America's homeland defense
industry as well as advanced technologies for diabetes management and
rapid medical testing, today announced it has signed a Teaming Agreement
("Teaming Agreement") with Science Applications International
Corporation ("SAIC") (SAI) to pursue the Defense Threat Reduction Agency
("DTRA") Indefinite Delivery/Indefinite Quantity ("IDIQ") Multiple
Award Contracts supporting the Weapons of Mass Destruction ("WMD") -
Defeat Technology, Arms Control, and Nuclear Technology Electromagnetic
Research and Development/ Survivability and Infrastructure programs.
The Teaming Agreement pairs SAIC's system engineering and
integration capabilities with PositiveID's bio-threat detection
technologies. PositiveID will offer both its Dragonfly(TM) Rapid MD-x
Cartridge-based diagnostic system ("Dragonfly") as well as its M-BAND
(Microfluidics-based Bioagent Networked Detector) airborne bio-threat
detector as part of the Teaming Agreement.
PositiveID's Dragonfly system is designed to deliver molecular
diagnostic results from a sample in less than 30 minutes, which would
enable accurate diagnostics leading to potential treatment scenarios at
the point of care that are not possible with existing systems. Dragonfly
is being developed further for a broad range of biological detection
situations including radiation-induced cell damage within the human
body, strains of influenza and other common pathogens and diseases such
as E. coli, methicillin-resistant staphylococcus aureus ("MRSA") and
human papilloma virus ("HPV").
PositiveID's M-BAND, developed under contract for the Department of
Homeland Security Science and Technology Division, is a bioaerosol
monitor with fully integrated systems with sample collection, processing
and detection modules that continuously analyze air samples for the
detection of bacteria, viruses, and toxins with results in as little as
two hours. Results from individual M-BAND instruments are reported via a
secure wireless network in real time to give an accurate and up to date
status for fielded instruments in the aggregate.
William J. Caragol, Chairman and CEO of PositiveID, stated, "We are
very pleased to team with SAIC through this agreement, and demonstrate
the value and capabilities of our Dragonfly and M-BAND technologies."
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer
of advanced technologies for diabetes management and rapid medical
testing, as well as airborne bio-threat detection systems for America's
homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or
MFS, is focused on the development of microfluidic systems for the
automated preparation of and performance of biological assays in order
to detect biological threats at high-value locations, as well as analyze
samples in a medical environment.
www.PositiveIDCorp.com.
The PositiveID Corporation logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7717
For more information on PositiveID, please visit
http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the
likelihood that it has made significant progress realigning its business
with a focus on its molecular diagnostics platform; the likelihood that
the Company also continues to make strong progress in the diabetes
management segment of its business; the likelihood that the Company will
enter into strategic partnerships and/or teaming agreements with large
government contractors for M-BAND manufacturing and system integration
for BioWatch Gen-3; the likelihood that the Company will submit a
proposal upon release of the final BioWatch Gen 3 RFP, currently
scheduled for release in the fourth quarter of calendar 2012, from
Department of Homeland Security for the $3.1 billion BioWatch Gen-3
procurement; the likelihood that the Company will commence the second
stage of Easy Check clinical study at Schneider Children's Medical
Center in Israel; the likelihood that the Company will complete a
bench-top unit of the GlucoChip glucose-sensor and initiate strategic
partnerships; the likelihood that the Company will continue development
of its Dragonfly Rapid MDx Cartridge-based diagnostic system for
point-of-care diagnostics; the likelihood that the Company will complete
the license and/or sale of the VeriChip and iglucose product lines to
position them with the best partners for market exploitation and
monetization; the likelihood that the Company will complete a strategic
financing to capitalize the Company to execute on these opportunities;
the likelihood that significant opportunities that lie ahead, including
BioWatch Gen 3 and the continued development of the Company's innovative
Dragonfly system; the likelihood that the Company will continue to
execute its plan, described above; the likelihood that the Company is
well positioned to capitalize on the BioWatch Gen 3 opportunity and to
make meaningful steps in the commercialization of our diabetes
management products; the likelihood that that progress, in conjunction
with a strategic financing to fully capitalize the Company, will allow
the Company to unlock value for stockholders; and all other statements
in this press release other than historical facts are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of
1933, Section 21E of the Securities Exchange Act of 1934, and as that
term is defined in the Private Litigation Reform Act of 1995. Such
forward-looking statements involve risks and uncertainties and are
subject to change at any time, and PositiveID's actual results could
differ materially from expected results. These risks and uncertainties
include PositiveID's ability to successfully commercialize its M-BAND
system and Dragonfly system, as well as its diabetes management
products; the Company's ability to complete the license and/or sale of
the VeriChip and iglucose product lines to position them with the best
partners for market exploitation and monetization; the Company's ability
to attract strategic partners; the Company's ability to complete a
strategic financing; as well as certain other risks. Additional
information about these and other factors that could affect the
Company's business is set forth in the Company's various filings with
the Securities and Exchange Commission, including those set forth in the
Company's 10-K filed on March 28, 2012, and 10-Qs filed on August 20,
2012, May 14, 2012, and November 14, 2011, under the caption "Risk
Factors." The Company undertakes no obligation to update or release any
revisions to these forward-looking statements to reflect events or
circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Disclaimer/ Disclosure: Disclaimer: Our sites do
not make recommendations. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. We attempt
to research thoroughly, but we offer no guarantees as to the accuracy
of information presented. All Information relating to featured companies
is sourced from public documents and/ or the company and is not the
opinion of our web sites. This site is currently compensated by featured
companies, news submissions and online advertising. More info:
www.InvestorIdeas.com/About/Disclaimer.asp
and disclosures: PositiveID Corporation compensates Investorideas.com
for news release publication, syndication on blogs and related sites and
email distribution and company profile: renewed July 2012 -3500 cash
and five hundred thousand shares for three months
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
Decision Diagnostics Corp. (OTCBB: DECN) Lead Product; GenStrip ® Blood Glucose Test Strips 
In March 2012 and then again September 2012 representatives of
the company and Shasta Technologies LLC met face-to-face with the FDA to
ask questions and respond to FDA comments and to present its case in an
effort to complete the FDA review process. Subsequently Shasta
Technologies LLC and the company have received and responded to a short
series of follow up questions and comments by FDA. 
